Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2018 Financial Results Business Wire
First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program, ALPN-101; Completed $25 Million Private Placement; Strong …